<p>Tiziana Life Sciences Ltd（纳斯达克代码：TLSA - 获取免费报告）周四股价下跌 4.4%。该公司最低交易价格为 1.70 美元，最后交易价格为 1.72 美元。在午盘交易中，共成交 145,761 股，较平均交易量 249,876 股下降了 42%。该股票此前收盘价为 1.80 美元。</p>
<p>获取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
<h2>分析师设定新的价格目标</h2>
<p>另外，Weiss Ratings 在 10 月 8 日的报告中重申了对 Tiziana Life Sciences 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “卖出”。</p>
<p><strong>查看我们最新的 TLSA 股票分析</strong></p>
<h2>Tiziana Life Sciences 股票下跌 4.4%</h2>
<p>该公司的 50 日移动平均价格为 1.86 美元，200 日移动平均价格为 1.79 美元。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第三季度购买了价值约 520,000 美元的 Tiziana Life Sciences 新股份。Jane Street Group LLC 在第一季度将其在 Tiziana Life Sciences 的持股增加了 968.2%。Jane Street Group LLC 目前拥有 167,542 股该公司的股票，价值 181,000 美元，此前在上一季度又购买了 151,858 股。OMERS ADMINISTRATION Corp 在第一季度收购了价值 156,000 美元的 Tiziana Life Sciences 新股份。Bison Wealth LLC 在第四季度购买了价值 30,000 美元的 Tiziana Life Sciences 新股份。最后，ARS Investment Partners LLC 在第三季度购买了价值 66,000 美元的 Tiziana Life Sciences 新股份。</p>
<h2>关于 Tiziana Life Sciences</h2>
<p>（获取免费报告）</p>
<p>Tiziana Life Sciences Ltd 是一家生物技术公司，专注于发现和开发治疗肿瘤学和免疫学人类疾病的分子。该公司在免疫学领域的主要产品候选药物是 Foralumab（TZLS-401），这是一种人源性抗 CD3 单克隆抗体（mAb），用于治疗克罗恩病、移植物抗宿主病、溃疡性结肠炎、多发性硬化症、1 型糖尿病、炎症性肠病、银屑病和类风湿关节炎等疾病。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Tiziana Life Sciences</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>2026 年应避免的三只最近被下调评级的股票</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Tiziana Life Sciences 吗？</h2>
<p>在考虑 Tiziana Life Sciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Tiziana Life Sciences 并不在名单上。</p>
<p>虽然 Tiziana Life Sciences 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TLSA

<p>Tiziana Life Sciences (NASDAQ:TLSA) 的股价下跌了 4.4%，至 1.72 美元，交易量较平均水平下降了 42%。Weiss Ratings 重申了 “卖出” 评级，该股票的共识评级为 “卖出”。机构投资者已调整其持股，有些增加了持股，有些则减少了持股。Tiziana 专注于开发肿瘤学和免疫学领域的疾病治疗方案。尽管当前的评级为 “卖出”，分析师建议其他股票作为更好的投资选择</p>

<p>Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price fell 4.4% on Thursday . The company traded as low as $1.70 and last traded at $1.72. 145,761 shares traded hands during mid-day trading, a decline of 42% from the average session volume of 249,876 shares. The stock had previously closed at $1.80.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd（纳斯达克代码：TLSA - 获取免费报告）周四股价下跌 4.4%。该公司最低交易价格为 1.70 美元，最后交易价格为 1.72 美元。在午盘交易中，共成交 145,761 股，较平均交易量 249,876 股下降了 42%。该股票此前收盘价为 1.80 美元。</p>
</div><p>Get <strong>Tiziana Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>Separately, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Tiziana Life Sciences in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 8 日的报告中重申了对 Tiziana Life Sciences 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “卖出”。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TLSA</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TLSA 股票分析</strong></p>
</div><h2>Tiziana Life Sciences Stock Down 4.4%</h2>
<div class="lb-trans"><h2>Tiziana Life Sciences 股票下跌 4.4%</h2>
</div><p>The business's 50 day moving average price is $1.86 and its 200-day moving average price is $1.79.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 1.86 美元，200 日移动平均价格为 1.79 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new stake in shares of Tiziana Life Sciences in the 3rd quarter valued at approximately $520,000. Jane Street Group LLC boosted its stake in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after buying an additional 151,858 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at $156,000. Bison Wealth LLC bought a new stake in Tiziana Life Sciences in the fourth quarter valued at $30,000. Finally, ARS Investment Partners LLC bought a new stake in Tiziana Life Sciences in the third quarter valued at $66,000.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。Millennium Management LLC 在第三季度购买了价值约 520,000 美元的 Tiziana Life Sciences 新股份。Jane Street Group LLC 在第一季度将其在 Tiziana Life Sciences 的持股增加了 968.2%。Jane Street Group LLC 目前拥有 167,542 股该公司的股票，价值 181,000 美元，此前在上一季度又购买了 151,858 股。OMERS ADMINISTRATION Corp 在第一季度收购了价值 156,000 美元的 Tiziana Life Sciences 新股份。Bison Wealth LLC 在第四季度购买了价值 30,000 美元的 Tiziana Life Sciences 新股份。最后，ARS Investment Partners LLC 在第三季度购买了价值 66,000 美元的 Tiziana Life Sciences 新股份。</p>
</div><h2>About Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>关于 Tiziana Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd 是一家生物技术公司，专注于发现和开发治疗肿瘤学和免疫学人类疾病的分子。该公司在免疫学领域的主要产品候选药物是 Foralumab（TZLS-401），这是一种人源性抗 CD3 单克隆抗体（mAb），用于治疗克罗恩病、移植物抗宿主病、溃疡性结肠炎、多发性硬化症、1 型糖尿病、炎症性肠病、银屑病和类风湿关节炎等疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Tiziana Life Sciences</li>
<li>ESG Stocks, What Investors Should Know</li>
<li>3 Recently Downgraded Stocks to Avoid in 2026</li>
<li>How to Calculate Retirement Income: MarketBeat’s Calculator</li>
<li>The Chip Boom Is Back: 3 Stocks Positioned for Huge Gains</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>Oracle Stock Hit Hard: Why Its AI Pipeline Could Drive a 2026 Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Tiziana Life Sciences</li>
<li>ESG 股票，投资者应了解的事项</li>
<li>2026 年应避免的三只最近被下调评级的股票</li>
<li>如何计算退休收入：MarketBeat 的计算器</li>
<li>芯片热潮回归：三只有望大幅上涨的股票</li>
<li>内部人士卖出解释：这能否影响你的投资选择？</li>
<li>甲骨文股票遭重创：为何其 AI 管道可能推动 2026 年反弹</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tiziana Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Tiziana Life Sciences 吗？</h2>
</div><p>Before you consider Tiziana Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tiziana Life Sciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Tiziana Life Sciences 并不在名单上。</p>
</div><p>While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tiziana Life Sciences 目前在分析师中被评为卖出评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tiziana Life Sciences（NASDAQ:TLSA）股价下跌 4.4% - 以下是原因